Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs

相似书籍

• Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
  由: Jae Cheol Lee, et al.
  出版: (2021-05-01)
• Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
  由: Jerry Shu-Hung Kuo, et al.
  出版: (2025-01-01)
• Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
  由: Asako Matsuda, et al.
  出版: (2019-12-01)
• Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer
  由: Eun Hye Lee, et al.
  出版: (2024-08-01)
• Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
  由: Hsu-Yuan Chen, et al.
  出版: (2024-10-01)